Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

392
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
392

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifocal Neuroblastoma in Rubinstein-Taybi Syndrome Harboring a Novel CREBBP Variant Identified by Paired Whole Genome Sequencing.

Congenital anomalies·2026
Same author

Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.

British journal of haematology·2026
Same author

Phenotypic Expansion and Molecular Implications in Recessive FUZ -Related Ciliopathy.

Clinical genetics·2026
Same author

Trends in procedural closure of patent ductus arteriosus among children from 2011 to 2022 in Japan.

Pediatrics international : official journal of the Japan Pediatric Society·2026
Same author

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph<sup>+</sup> Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Pediatric blood & cancer·2026
Same author

Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12).

British journal of haematology·2026
Same journal

Modified short-course fludarabine-based conditioning regimen for salvage cord blood transplantation after graft failure.

International journal of hematology·2026
Same journal

Cytarabine-based induction and oral maintenance therapy for a single system with single-site Langerhans cell histiocytosis.

International journal of hematology·2026
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
Same journal

The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis.

International journal of hematology·2026
Same journal

Current status and challenges of TCR-T cell therapy for AML/MDS.

International journal of hematology·2026
See all related articles

Related Experiment Video

Updated: Aug 19, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Recent progress in pediatric lymphoblastic leukemia.

Motohiro Kato1

  • 1Department of Pediatrics, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. katom-tky@umin.ac.jp.

International Journal of Hematology
|December 1, 2022
PubMed
Summary
This summary is machine-generated.

Childhood lymphoblastic leukemia survival has dramatically improved due to genomic analysis, leading to better prognoses and reduced relapse rates with risk-adjusted chemotherapy. Ongoing research in genomics, minimal residual disease, and immunotherapy promises further survival gains.

Keywords:
B-otherImmunotherapyInherited variationMinimal residual disease

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K

Related Experiment Videos

Last Updated: Aug 19, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K

Area of Science:

  • Pediatric Oncology
  • Genomic Medicine
  • Hematology

Background:

  • Childhood lymphoblastic leukemia (ALL) survival rates have significantly increased.
  • Advances in genomic analysis have enhanced understanding of leukemic cells and treatment response.
  • Germline variations are increasingly recognized for their role in ALL treatment outcomes.

Purpose of the Study:

  • To review the impact of genomic analysis on improving survival in childhood ALL.
  • To highlight the role of risk-adjusted chemotherapy and its benefits.
  • To discuss emerging therapeutic strategies and future research directions.

Main Methods:

  • Review of recent advances in genomic analysis techniques for ALL.
  • Analysis of risk-adjusted chemotherapy protocols and their outcomes.
  • Examination of minimal residual disease assays and immunotherapy.

Main Results:

  • Genomic insights have improved prognostic prediction and treatment response evaluation.
  • Risk-adjusted chemotherapy has reduced relapse rates and treatment complications.
  • Germline variation studies are revealing new insights into ALL pathogenesis.

Conclusions:

  • Genomic advances are central to improved survival in childhood ALL.
  • Minimal residual disease assays and immunotherapy hold promise for further therapeutic improvements.
  • Continued clinical and translational research aims for 100% survival in ALL.